Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Daraxonrasib + Gemcitabine + Nab-paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Daraxonrasib | RMC 6236|RMC6236|RMC-6236 | RAS Inhibitor (Pan) 13 | Daraxonrasib (RMC-6236) forms a binary complex with CypA, which prevents GTP-bound RAS from interacting with downstream effectors, potentially leading to anti-tumor activity (Cancer Res 2022;82(12_Suppl): Abstract nr 3597, PMID: 38593348). | |
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
Nab-paclitaxel | Abraxane | ABI-007|Paclitaxel Protein-bound | Chemotherapy - Taxane 3 | Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06445062 | Phase Ib/II | Cetuximab + Daraxonrasib + Fluorouracil + Leucovorin + Oxaliplatin Daraxonrasib + Gemcitabine + Nab-paclitaxel Bevacizumab + Daraxonrasib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Daraxonrasib Bevacizumab + Daraxonrasib + Fluorouracil + Leucovorin + Oxaliplatin | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Recruiting | USA | 0 |